Search Results - "Xiaocheng Li-Sucholeiki"

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes by May, Theresa, Clement, Michelle S, Halait, Harkanwal, Kohlmann, Alexander, Kohlmann, Milena, Lai, Jason, Lee, Nitta, Li-Sucholeiki, Xiaocheng, Meldgaard, Peter, Joshi, Snehal, Scudder, Sidney, Shrestha, Neelima, Sorensen, Boe, Kiral, Marilyn, O'Donnell, Patrick

“…Survival rates in non-small cell lung cancer (NSCLC) are low. Detection of circulating tumor DNA in liquid biopsy (plasma) is increasingly used to identify…”
Get full text

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer by Gray, Jhanelle E, Okamoto, Isamu, Sriuranpong, Virote, Vansteenkiste, Johan, Imamura, Fumio, Lee, Jong Seok, Pang, Yong-Kek, Cobo, Manuel, Kasahara, Kazuo, Cheng, Ying, Nogami, Naoyuki, Cho, Eun Kyung, Su, Wu Chou, Zhang, Guili, Huang, Xiangning, Li-Sucholeiki, Xiaocheng, Lentrichia, Brian, Dearden, Simon, Jenkins, Suzanne, Saggese, Matilde, Rukazenkov, Yuri, Ramalingam, Suresh S

“…To assess the utility of the EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with -mutated ( m; Ex19del and/or…”
Get full text

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD) by Yu, Helena A., Goldberg, Sarah B., Le, Xiuning, Piotrowska, Zofia, Goldman, Jonathan W., De Langen, Adrianus J., Okamoto, Isamu, Cho, Byoung Chul, Smith, Paul, Mensi, Ilhem, Ambrose, Helen, Kraljevic, Silvija, Maidment, Julie, Chmielecki, Juliann, Li-Sucholeiki, Xiaocheng, Doughton, Gail, Patel, Gargi, Jewsbury, Phil, Szekeres, Phil, Riess, Jonathan W.

“…Osimertinib, a third-generation, irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), selectively inhibits both EGFR-TKI…”
Get full text

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR -mutant, MET -driven ( MET +), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib by Oxnard, Geoffrey R., Cantarini, Mireille, Frewer, Paul, Hawkins, George, Peters, Jane, Howarth, Paul, Ahmed, Ghada F., Sahota, Tarjinder, Hartmaier, Ryan, Li-Sucholeiki, Xiaocheng, Ahn, Myung-Ju

“…Abstract only TPS9119 Background: The toxicity profile of the third-generation EGFR-tyrosine kinase inhibitor (TKI) osimertinib makes it an attractive backbone…”
Get full text

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes by Theresa May, Michelle S. Clement, Harkanwal Halait, Alexander Kohlmann, Milena Kohlmann, Jason Lai, Nitta Lee, Xiaocheng Li-Sucholeiki, Peter Meldgaard, Snehal Joshi, Sidney Scudder, Neelima Shrestha, Boe Sorensen, Marilyn Kiral, Patrick O’Donnell

Get full text